Global office locator

Attending AASLD The Liver Meeting? Connect with ICON’s hepatology experts at booth \#1861, to explore how we can support your liver disease trials, from smarter site selection powered by AI and expert insight to imaging,...

The evidence requirements for biosimilar development in Europe continue to evolve. For well-characterised biologics, robust analytical comparability, pharmacokinetic evidence and an appropriate safety assessment may sup...

As biosimilar regulations evolve, development teams must adapt their analytical strategies to meet changing expectations. In BioProcess International, authors Kimberly Salgado & Radboud van Trigt outline key considerati...

Attending #ObesityWeek on Nov 14–17? Meet us as booth \#212 to learn how our comprehensive lab and imaging capabilities support high-quality, large-scale obesity studies. From AI-driven imaging biomarkers to expert guida...

ICON has launched the FIRECREST AI-directed video engine, bringing greater speed, scale and consistency to clinical trial communications. Built for regulated environments, the new capability can reduce video production ...

Between 2020 and 2024, the FDA has approved a string of first-ever targeted treatments for early-stage chronic conditions, including MASLD, Obesity and Alzheimer's. ICON experts explore the pivotal role that biomarker-ba...

Which journals have the biggest impact? We can tell you. PubsHub Journals & Congresses gives you access to over 10,000 options for publishing your work, with 50 important data fields to consider and compare. Fast and eas...

Around 600 colleagues from our Chennai office recently came together for the first movie event organised by our India Employee Recreation Club (IERC). Held at PVR Cinemas in Velachery, the event saw colleagues fill two ...

Meet us at AASLD, booth \#1861 to learn how our deep expertise in imaging-based hepatic biomarkers and global operational support help sponsors optimise trial design and accelerate the delivery of MASH treatments to pati...

As clinical development becomes more complex and data-driven, operating models need to evolve to support faster, more confident decision-making. This latest blog explores how FSP, FSO and hybrid approaches can be aligned...

Keeping patients engaged across multi-year follow-ups presents a serious hurdle for non-oncology immunotherapy trials. Read our whitepaper to discover how sponsors can curb attrition and support long-term safety monitori...

Emerging approaches to first-in-human studies are helping sponsors obtain meaningful clinical insights sooner through integrated study designs, stronger patient engagement, and strategic biomarker implementation. In thi...